UK Medicines and Healthcare Products Regulatory Agency Approves CBD

The British government on Tuesday announced it is backing products containing a specific cannabinoid (a component of marijuana). Government health authorities have  given private companies 28 days to get licenses to sell their products. The UK Medicines and Healthcare Products Regulatory Agency will approve products with the ingredient cannabidiol, commonly known as CBD. CBD is non psychoactive and does not produce the euphoric “high” associated with THC. Multiple scientific studies have previously shown that cannabidiol is responsible for a plethora of marijuana’s therapeutic effects. Researchers have found that CBD can treat certain kinds of pain, PTSD, chrohn’s disease, MS, and epilepsy.

Medical Cannabis Studies In UK

Now that the British government is promoting the therapeutic effects of marijuana, researchers are hoping that the government will also support more studies on marijuana as well. Cannabis is such a complex medicinal plant, the medical and scientific world is just starting to scratch the surface of its potential. With more understanding on how CBD effects the endocannibinoid system, we can start to unlock the unknown benefits of the plant.

Many researchers in the UK aim to reveal those secrets. Marijuana has remained an illegal drug in the UK, labeled as having no “therapeutic value.” Anyone using the drug without government permission can be charged with possession. At this time requesting legal use of the drug, even for medical purposes, remains difficult in the UK.

For years supporters have argued that use of marijuana, a Class B drug ( in the same class as amphetamines, barbiturates, codeine,  cathinones and synthetic cannabinoids) should be decriminalized. A milestone moment for the campaign to legalize cannabis – the government’s Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that Cannabidiol (CBD) has a “restoring, correcting or modifying” effect on “physiological functions” when given to people.

The maximum penalty for possession of cannabis is five years in prison. There are also penalties for dealing, production and trafficking of up to 14 years in prison, an unlimited fine, or both.

The MHRA assessment:

“The MHRA has now completed it’s review and has considered all information available to it relating to Cannabidiol(CBD) and having taken into account all the scientific advice and evidence, it has come to an opinion that products containing Cannabidiol will satisfy the second limb of the definition of a ‘medicinal product’ because it may be used by or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.”

Comments

Medical Marijuana 411 values providing our readers with information about the latest cannabis related topics for educational purposes and not for the intention of advocacy. This is not an advocacy-based organization. For ailment specific questions, please consult your primary care physician.